Traditional Chinese medicine composition for treating preventricular constriction and application thereof

Abstract

The invention discloses a traditional Chinese medicine composition for treating preventricular constriction and application thereof, and relates to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10-30 parts of cassia twig, 5-20 parts of honey-fried licorice root, 20-50 parts of calcined dragon bone, 20-50 parts of calcined oyster shell, 5-20 parts of cinnamon, 10-30 parts of salvia miltiorrhiza, 10-30 parts of ligusticum wallichii, 5-20 parts of radix bupleuri, 5-20 parts of radix paeoniae alba, 2-20 parts of fructus aurantii, 10-30 parts of radix sophorae flavescentis, 5-20 parts of rhizoma nardostachyos and 10-30 parts of parasitic loranthus. The traditional Chinese medicine composition provided by the invention has the effects of exciting heart yang, removing blood stasis, dredging collaterals, nourishing heart and calming palpitation, can effectively treat presexual presexual contraction, and has great social value for widening the current method for treating frequent presexual presexual contraction and promoting flourishing development of the traditional Chinese medicine career.

Description

Technical Field

[0001] The present invention relates to the technical field of traditional Chinese medicine, and in particular to a traditional Chinese medicine composition for treating premature ventricular contractions and application thereof. Background Art

[0002] Premature ventricular contracts (PVCs), also known as premature ventricular contractions (PVCs), are premature contractions caused by premature depolarization of ectopic pacemakers within the His bundle and its branches. Epidemiological studies show an incidence of approximately 1% to 4%, with 24-hour Holter monitoring showing an incidence rate exceeding 40%. The incidence increases significantly with age. The clinical manifestations of PVCs vary greatly depending on the patient's sympathetic nervous system activity, including palpitations, a feeling of cardiac arrest, and a foreign body sensation in the throat. These symptoms often occur during daytime periods of sympathetic nervous system activity, and most patients may be asymptomatic. However, patients with occasional PVCs may still experience significant clinical symptoms. Frequent PVCs can lead to decreased cardiac output, and inadequate blood perfusion to vital organs can cause symptoms such as chest tightness, dizziness, fatigue, syncope, and blackouts, severely impacting the patient's quality of life.

[0003] Modern medicine believes that the mechanism of ventricular premature beats is the increased automaticity of the ventricular muscle caused by the ectopic pacemaker, and premature or late depolarization triggers premature contraction. Any factor that can cause premature depolarization of ventricular muscle cells is the cause of ventricular premature beats, including structural heart disease (coronary atherosclerotic heart disease, cardiomyopathy, valvular heart disease), electrolyte disorders (hypokalemia, hypomagnesemia), and drug poisoning (digitalis, quinidine, tricyclic antidepressant poisoning) are all common causes of ventricular premature beats. In addition, various bad habits, such as excessive intake of alcohol, coffee, and tea, smoking, mental stress, and excessive fatigue can also induce ventricular premature beats.

[0004] In current clinical practice, the treatment of frequent premature ventricular contractions is primarily divided into medication and surgery. Medication options primarily include antiarrhythmic drugs, such as beta-blockers and non-dihydropyridine calcium channel blockers. Although oral Western medication is currently the most common treatment for frequent premature ventricular contractions, both beta-blockers and non-dihydropyridine calcium channel blockers have negative inotropic and negative conduction effects, further slowing the heart rate and reducing myocardial contractility, potentially inducing bradyarrhythmias. Furthermore, improvement in clinical symptoms varies with individual patient constitutions, and long-term use can easily lead to drug resistance and significant toxic side effects. For patients who have inadequate responses to Western medication or for whom Western medication is contraindicated, catheter radiofrequency ablation (RFA) is often the treatment of choice. However, this technique is invasive, expensive, and associated with numerous postoperative complications. Despite being a safe, feasible, and effective treatment, patient acceptance remains limited. Traditional Chinese medicine (TCM) compound formulas can act on multiple ion channels and targets, allowing for tailored treatment tailored to the patient's constitution. These formulas offer significant improvement in clinical symptoms, minimal side effects, long-lasting efficacy, and high patient compliance. Given these factors, developing a safe and effective TCM combination for the treatment of ventricular premature beats is crucial for broadening current treatment options for frequent ventricular premature beats and promoting the vigorous development of Traditional Chinese Medicine. Summary of the Invention

[0005] The present invention aims to provide a Chinese medicine composition for treating premature ventricular contractions and its application, so as to solve the problems existing in the above-mentioned prior art. The Chinese medicine composition provided by the present invention has the efficacy of treating frequent premature ventricular contractions.

[0006] To achieve the above object, the present invention provides the following solutions:

[0007] The invention provides a traditional Chinese medicine composition for treating premature ventricular contractions. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10-30 parts of cassia twig, 5-20 parts of roasted liquorice root, 20-50 parts of calcined dragon bone, 20-50 parts of calcined oyster shell, 5-20 parts of cinnamon bark, 10-30 parts of salvia miltiorrhiza, 10-30 parts of chuanxiong, 5-20 parts of bupleurum root, 5-20 parts of white peony root, 2-20 parts of fructus aurantii, 10-30 parts of sophora flavescens, 5-20 parts of nardus thunbergii and 10-30 parts of parasitic plant.

[0008] Furthermore, the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10-20 parts of cinnamon twig, 5-15 parts of roasted liquorice root, 20-30 parts of calcined dragon bone, 20-30 parts of calcined oyster shell, 10-20 parts of cinnamon bark, 10-20 parts of salvia miltiorrhiza, 10-20 parts of chuanxiong, 5-15 parts of bupleurum, 5-15 parts of white peony root, 5-15 parts of fructus aurantii, 10-20 parts of sophora flavescens, 5-15 parts of nardus thunbergii and 10-20 parts of mistletoe.

[0009] Furthermore, the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 15 parts of cinnamon twig, 10 parts of roasted liquorice root, 25 parts of calcined dragon bone, 25 parts of calcined oyster shell, 15 parts of cinnamon bark, 15 parts of salvia miltiorrhiza, 15 parts of chuanxiong, 10 parts of bupleurum, 10 parts of white peony root, 10 parts of fructus aurantii, 15 parts of sophora flavescens, 10 parts of nardus thunbergii and 15 parts of mistletoe.

[0010] Furthermore, the traditional Chinese medicine composition also includes a pharmaceutically acceptable carrier.

[0011] The "pharmaceutically acceptable" ingredients of the present invention are ingredients that are suitable for use in humans and / or animals and have no excessive adverse side effects (eg, toxicity, irritation, etc.), that is, substances with a reasonable benefit-risk ratio.

[0012] As used herein, "pharmaceutically acceptable carrier" refers to a carrier used for administering a therapeutic agent, including various excipients, diluents, and the like. The carrier itself does not necessarily possess the relevant pharmaceutical activity, but should be non-undue toxic upon use. Specific carriers are well known to those skilled in the art. The specific form may be either liquid or solid. The carrier may also have certain auxiliary functions, such as an emulsifier, filler, binder, disintegrant, colorant, and solubilizer.

[0013] Furthermore, the dosage form of the Chinese medicine composition is an oral dosage form.

[0014] Furthermore, the oral dosage form is a decoction.

[0015] The present invention also provides the use of the above-mentioned traditional Chinese medicine composition in preparing a medicine for treating premature ventricular contractions.

[0016] Furthermore, the treatment of ventricular premature contractions includes reducing the number of ventricular premature contraction attacks, reducing the 24-hour ventricular premature contraction load, and improving clinical symptoms of palpitations and cardiac arrest.

[0017] Furthermore, the drug for treating premature ventricular contractions includes a Chinese patent medicine prepared solely from the Chinese medicine composition, or a Chinese and Western medicine composite preparation prepared by adding a chemical drug conventionally used in clinical treatment of arrhythmias.

[0018] The present invention discloses the following technical effects:

[0019] Chinese medicine composition of the present invention is made up of 13 common Chinese medicines of cinnamon twig, preparatory liquorice root, calcined dragon bone, calcined oyster, cinnamon bark, salvia miltiorrhiza, ligusticum chuanxiong, bupleurum, the white peony root, fructus aurantii, sophora flavescens, rhizoma nardostachyos and herba parasiticae, and applied medicine mostly belongs to heart meridian, and nature and flavor are pungent, sweet, flat. Traditional Chinese medicine thinks that the heart belongs to fire viscera, is the yang among yang, controls blood vessels, and yang-qi is abundant, promotes blood circulation to flow smoothly, and the mind is at peace, and heart rhythm is regular. When the elderly are ill for a long time and are weak, or misuse cold food, medicine after the body is deficient in heart yang, it is difficult to continue to promote the operation of heart blood, so blood circulation is stagnant, blood vessels are not smooth, heart rate is sometimes fast and sometimes slow, and there is a sense of stopping from time to time, and the symptoms such as palpitation, premature ejaculation, chest tightness, shortness of breath come thereupon. This Chinese medicine combination follows the principle of monarch, minister, assistant and envoy, with rigorous compatibility and orderly organization. It uses the ancient prescription "Guizhi Gancao Longgu Muli Decoction" from "Treatise on Febrile Diseases" as the monarch, with cinnamon twig and licorice combined to replenish the heart's yang qi, and dragon bone and oyster combined to astringe and prevent the leakage of ying yin; it uses the classic prescription "Si Ni San" from "Golden Chamber" as the minister, with bupleurum, white peony root, aurantium, and roasted licorice to reach the triple burner, circulate the ying and wei, and make the blood carry qi and qi help blood production; cinnamon bark and mistletoe are the assistants, warming and nourishing kidney yang, so that the heart and kidney can communicate, and the monarch and minister fires complement each other, just as recorded in "Jingyue Complete Works": monarch fire is bright, the heart meridian is spiritual, and the heart rhythm is regular; monarch fire is strong, the kidney yang is warmed and dispersed, and the source circulates continuously; sophora flavescens, sweet pinellia, salvia miltiorrhiza, and Chuanxiong are the envoys, which promote qi and resolve stagnation, activate blood circulation and remove blood stasis, strengthen the function of activating blood circulation and promoting qi, and prevent qi stagnation and blood stasis from blocking the meridians and inhibiting heart yang.

[0020] The Chinese medicine composition provided by the present invention has the effects of attacking and tonifying, astringing while promoting circulation, collecting while dispersing, treating both the symptoms and the root causes, with rigorous formula and proper compatibility, taking into account "expelling evil without harming the body, and tonifying deficiency without leaving the enemy", fully embodying the advantages of multi-dimensional and multi-target treatment of traditional Chinese medicine, and can not only effectively improve the clinical symptoms of patients with frequent ventricular premature beats, but also effectively reduce the number of ventricular premature contractions, reduce the 24-hour ventricular premature contraction load, improve clinical symptoms of palpitations and cardiac arrest, improve the daily quality of patients, and have significant clinical efficacy without obvious toxic side effects and adverse reactions. It not only solves clinical problems, but also broadens the current methods for treating frequent ventricular premature beats, promotes the vigorous development of traditional Chinese medicine, and has great social value. DETAILED DESCRIPTION

[0021] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but rather as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0022] It should be understood that the terms described herein are intended only to describe particular embodiments and are not intended to limit the present invention. In addition, for numerical ranges herein, it should be understood that each intermediate value between the upper and lower limits of the range is also specifically disclosed. The intermediate value within any stated value or stated range, and each smaller range between any other stated value or intermediate value within the stated range, is also encompassed within the present invention. The upper and lower limits of these smaller ranges may be independently included or excluded within the scope.

[0023] Unless otherwise indicated, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art. Although only preferred methods and materials are described herein, any methods and materials similar or equivalent to those described herein may also be used in the practice or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of any conflict with any incorporated document, the contents of this specification shall prevail.

[0024] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments described herein without departing from the scope or spirit of the invention. Other embodiments will be apparent to those skilled in the art from the description of the invention. The description and examples are intended to be exemplary only.

[0025] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0026] In the preparation method of the dosage form of the Chinese medicine composition in the following examples, the decoction is prepared by washing the weighed raw materials and boiling them in water. The volume ratio of the total raw materials to water is 1:1.5. The decoction is performed twice, each time for 1 hour, and the medicinal liquids obtained from the two decoctions are combined.

[0027] Example 1

[0028] This embodiment provides a decoction of Chinese patent medicine prepared from the following Chinese medicine composition in parts by weight:

[0029] 15 parts of cinnamon twigs, 10 parts of roasted liquorice root, 25 parts of calcined dragon bones, 25 parts of calcined oyster shells, 15 parts of cinnamon bark, 15 parts of salvia miltiorrhiza, 15 parts of ligusticum chuanxiong, 10 parts of bupleurum, 10 parts of white peony root, 10 parts of fructus aurantii, 15 parts of sophora flavescens, 10 parts of nardostachys, and 15 parts of herba mosquitoes.

[0030] Example 2

[0031] This embodiment provides a decoction of a Chinese patent medicine prepared from the following Chinese medicine composition in parts by weight:

[0032] 30 parts of cinnamon twigs, 20 parts of roasted liquorice root, 50 parts of calcined dragon bones, 50 parts of calcined oyster shells, 20 parts of cinnamon bark, 30 parts of salvia miltiorrhiza, 30 parts of chuanxiong, 20 parts of bupleurum, 20 parts of white peony root, 20 parts of fructus aurantii, 30 parts of sophora flavescens, 20 parts of nardostachys, and 30 parts of mistletoe.

[0033] Example 3

[0034] This embodiment provides a decoction of a Chinese patent medicine prepared from the following Chinese medicine composition in parts by weight:

[0035] 10 parts of cinnamon twigs, 5 parts of roasted liquorice root, 20 parts of calcined dragon bones, 20 parts of calcined oyster shells, 5 parts of cinnamon bark, 10 parts of salvia miltiorrhiza, 10 parts of chuanxiong, 5 parts of bupleurum, 5 parts of white peony root, 2 parts of fructus aurantii, 10 parts of sophora flavescens, 5 parts of nardostachys, and 10 parts of mistletoe.

[0036] Comparative Example 1

[0037] This comparative example provides a decoction of a Chinese patent medicine prepared from the following Chinese medicine compositions in parts by weight:

[0038] 35 parts of cinnamon twigs, 25 parts of roasted liquorice root, 15 parts of calcined dragon bones, 15 parts of calcined oyster shells, 25 parts of cinnamon bark, 35 parts of salvia miltiorrhiza, 23 parts of ligusticum chuanxiong, 4 parts of bupleurum, 4 parts of white peony root, 23 parts of fructus aurantii, 8 parts of sophora flavescens, 25 parts of rhizoma nardostachys, 35 parts of herba mosquitoes.

[0039] Comparative Example 2

[0040] This comparative example provides a decoction of a Chinese patent medicine prepared from the following Chinese medicine compositions in parts by weight:

[0041] 25 parts of cinnamon twigs, 25 parts of calcined dragon bones, 25 parts of calcined oyster shells, 15 parts of cinnamon bark, 15 parts of salvia miltiorrhiza, 35 parts of bupleurum, 10 parts of the white paeonia lactiflora, 10 parts of fructus aurantii, 15 parts of sophora flavescens, 10 parts of rhizoma nardostachys, 15 parts of herba mosilli.

[0042] Verification of the effects of Chinese patent medicines in each treatment group:

[0043] According to clinical case observations, the clinical efficacy of the finished products of Examples 1-3 of the present invention and Comparative Examples 1-2 in treating frequent ventricular premature beats was verified by the number of ventricular premature beats in 24 hours and the TCM clinical symptom score.

[0044] 1. Materials and Methods

[0045] 1. General Information

[0046] The research subjects were 180 cases of frequent premature ventricular contractions who were diagnosed and treated in the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine from July 2020 to July 2023 and met the inclusion and exclusion criteria.

[0047] 2. Diagnostic criteria

[0048] Western medicine diagnostic standards: formulated with reference to the relevant diagnostic standards for "ventricular premature beats" in the ninth edition of the "Internal Medicine" textbook edited by Ge Junbo et al. and the "Expert Consensus on Ventricular Arrhythmias" issued by the Chinese Medical Association.

[0049] ①Symptoms: Single ventricular premature beats may be asymptomatic, or may occasionally cause palpitations, chest tightness, and a feeling of cardiac arrest. Frequent ventricular premature beats can lead to reduced cardiac output and insufficient blood perfusion to vital organs, causing dizziness, fatigue, sweating, and even angina attacks.

[0050] ②Physical signs: When auscultating, premature heart beats can be heard, followed by a long interval. The second heart sound of ventricular premature beats is weakened or disappears, and the first heart sound is enhanced. Sometimes only the first heart sound can be heard. Pulse omission may be found when palpating the radial artery.

[0051] ③ECG manifestations: The premature appearance of a wide and deformed QRS-T wave, namely the ventricular depolarization wave, has a QRS wave duration usually greater than 0.12s. The T wave is in the opposite direction to the main QRS wave, with no related P wave preceding it and often followed by a complete compensatory pause.

[0052] Traditional Chinese Medicine diagnostic standards: Refer to the diagnostic standards for "palpitations" in "Traditional Chinese Medicine Internal Medicine" and "Guidelines for the Diagnosis and Treatment of Common Diseases in Traditional Chinese Medicine Internal Medicine" published by China Traditional Chinese Medicine Press in 2021.

[0053] 3. Inclusion criteria:

[0054] ① Meet the Western medical diagnostic criteria for premature ventricular contractions, with the number of premature ventricular contractions on the 24-hour dynamic electrocardiogram ≥2000 times; ② Meet the Traditional Chinese Medicine diagnostic criteria for palpitations; ③ Patients are 18 years or older and younger than 85 years old; ④ Patients who have previously taken Chinese herbal preparations related to cardiovascular diseases need to stop taking them for more than two weeks, and Western medicines need to be stopped for more than 5 half-lives to allow for metabolic clearance cycles; ⑤ Those who voluntarily sign the informed consent form, can persist in taking medication, and have good compliance.

[0055] 4. Exclusion criteria:

[0056] ① Patients who do not meet both Western medicine and traditional Chinese medicine diagnostic criteria; ② Patients with severe frequent premature ventricular beats, accompanied by frequent ventricular tachycardia, who require radiofrequency ablation; ③ Patients who have undergone PCI or CABG within the past 6 months, or patients with multi-vessel coronary artery disease or single coronary artery stenosis exceeding 70%; ④ Patients with frequent premature ventricular beats caused by acute myocardial infarction, acute heart failure, other systemic diseases (such as anemia, hyperthyroidism, etc.), digitalis poisoning, electrolyte imbalance, or ejection fraction <45%; ⑤ Patients with heart rate <60 beats / min, blood pressure <100 / 70 mmHg, or atrioventricular block, sick sinus syndrome; ⑥ Patients with serious heart, liver, kidney, hematopoietic system diseases or malignant tumors that seriously affect life; ⑦ Pregnant or lactating women, patients with mental illness; ⑧ Patients who are allergic to known ingredients of drugs.

[0057] 5. Termination criteria

[0058] ① Abnormalities in safety indicators such as liver function, renal function, and coagulation function occur during treatment; ② Acute diseases such as acute myocardial infarction, severe arrhythmia, and cardiogenic shock occur during treatment; ③ Special physiological conditions or unexpected events occur during the study; ④ Endpoint events such as patient death occur.

[0059] 6. Research Methods

[0060] 6.1 Treatment

[0061] 180 cases that met the inclusion and exclusion criteria were randomly divided into six groups: A, B, C, D, E and F, with 30 cases in each group. The general information of the six groups was comparable (P>0.05).

[0062] Group A: Orally take the Chinese medicine decoction prepared in Example 1, with a dosage of 100 ml / time, once in the morning, noon and evening, 30 minutes after meals, for a course of 8 weeks.

[0063] Group B: Orally take the Chinese medicine decoction prepared in Example 2, with a dosage of 100 ml / time, once in the morning, noon and evening, 30 minutes after meals, for a course of 8 weeks.

[0064] Group C: Orally take the Chinese medicine composition decoction prepared in Example 3, with a dosage of 100 ml / time, once in the morning, noon and evening every day, 30 minutes after meals, and a course of treatment of 8 weeks.

[0065] Group D: Orally take the Chinese medicine composition decoction prepared in Comparative Example 1, with a dosage of 100 ml / time, once in the morning, noon and evening every day, 30 minutes after meals, and a course of treatment of 8 weeks.

[0066] Group E: Orally take the Chinese medicine composition decoction prepared in Comparative Example 2, with a dosage of 100 ml / time, once in the morning, noon and evening every day, 30 minutes after meals, and a course of treatment of 8 weeks.

[0067] Group F: Oral administration of bisoprolol fumarate tablets (manufacturer: Beijing Huasu Pharmaceutical Co., Ltd.; specification: 5 mg; batch number: H20023132) 5 mg, once a day, for 8 weeks as a course of treatment.

[0068] During treatment, monitor blood pressure and heart rate. Do not take other antiarrhythmic Western medicines, Chinese patent medicines, or Chinese medicine products orally. Avoid drinking stimulating beverages such as spirits, coffee, and strong tea. Avoid eating spicy, greasy, raw, and cold foods. Avoid strenuous exercise. Patients with other underlying diseases should continue to take conventional Western medicine orally.

[0069] 6.2 Observation indicators

[0070] ①The number and proportion of ventricular premature beats in 24-hour dynamic electrocardiogram; ②Quality of life index score (SF-12).

[0071] 6.3 Safety evaluation

[0072] After the 8-week treatment, the patients' liver, kidney and coagulation functions, as well as blood, urine and stool routine tests were performed.

[0073] 6.4 Statistical Methods

[0074] SPSS 26.0 statistical software was used to analyze the data. Measurement data were expressed as "mean ± standard deviation". Paired t-test was used for comparison before and after treatment within the group, and independent sample t-test was used for comparison between groups before and after treatment; rank-sum test was used for comparison of rank data; chi-square test was used for enumeration data, with P < 0.05 considered statistically different and P < 0.01 considered significantly different.

[0075] 2. Research Results

[0076] During the study, 1 case dropped out in group A and 1 case dropped out in group B, 2 cases dropped out in group C, 1 case dropped out in group D and 1 case dropped out in group E, and 2 cases dropped out in group F.

[0077] (1) Number and proportion of premature ventricular contractions on 24-hour dynamic electrocardiogram

[0078] After treatment, the number and proportion of ventricular premature beats in the 24-hour dynamic electrocardiogram of the six groups of cases were improved (P < 0.05), among which the improvement in group A was more obvious (P < 0.01), see Table 1.

[0079] Table 1 Comparison of the number and proportion of premature ventricular beats in 24-hour dynamic electrocardiogram before and after treatment

[0080]

[0081]

[0082] Note: Compared with before treatment * P<0.05, compared with before treatment # P<0.01.

[0083] (2) Improvement in the Quality of Life Index

[0084] After treatment, the quality of life index score of group A increased from 45.66±3.01 to 50.31±2.26; the quality of life index score of group B increased from 42.77±2.80 to 48.70±1.35; the quality of life index score of group C increased from 42.51±1.65 to 47.37±1.28; after treatment, the quality of life index score of group D increased from 41.36±2.03 to 45.14±2.33; the quality of life index score of group E increased from 43.51±2.26 to 45.75±2.03; and the quality of life index score of group F increased from 44.93±2.33 to 46.76±2.09.

[0085] The quality of life score of the Chinese medicine composition in Example 1 was improved most significantly, and there was a statistically significant difference in the intra-group comparison (P<0.05), as shown in Table 2.

[0086] Table 2 Improvement of quality of life index scores

[0087] Group Number of cases Before treatment After treatment Group A 29 45.66±3.01 <![CDATA[50.31±2.26 * ]]> Group B 29 42.77±2.80 <![CDATA[48.70±1.35 * ]]> Group C 28 42.51±1.65 <![CDATA[47.37±1.28 * ]]> Group D 29 41.36±2.03 <![CDATA[45.14±2.33 * ]]> Group E 29 43.51±2.26 <![CDATA[45.75±2.03 * ]]> Group F 28 44.93±2.33 <![CDATA[46.76±2.09 * ]]>

[0088] Note: Compared with before treatment * P<0.05.

[0089] 3. Safety Evaluation

[0090] No adverse reactions were observed in the patients in each group during the 8-week medication period, and no abnormalities were found in the routine blood, urine, stool, liver and kidney functions.

[0091] The embodiments described above are merely descriptions of preferred embodiments of the present invention and are not intended to limit the scope of the present invention. Without departing from the spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by persons skilled in the art should fall within the scope of protection defined by the claims of the present invention.

Claims

1. A Chinese medicine composition for treating premature ventricular contractions, characterized in that: The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10-30 parts of cinnamon twig, 5-20 parts of roasted liquorice root, 20-50 parts of calcined dragon bone, 20-50 parts of calcined oyster shell, 5-20 parts of cinnamon bark, 10-30 parts of salvia miltiorrhiza, 10-30 parts of chuanxiong, 5-20 parts of bupleurum, 5-20 parts of white peony root, 2-20 parts of fructus aurantii, 10-30 parts of sophora flavescens, 5-20 parts of nardus thunbergii and 10-30 parts of mistletoe.

2. The Chinese medicine composition according to claim 1, characterized in that The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10-20 parts of cassia twig, 5-15 parts of roasted liquorice root, 20-30 parts of calcined dragon bone, 20-30 parts of calcined oyster shell, 10-20 parts of cinnamon bark, 10-20 parts of salvia miltiorrhiza, 10-20 parts of chuanxiong, 5-15 parts of bupleurum, 5-15 parts of white peony root, 5-15 parts of fructus aurantii, 10-20 parts of sophora flavescens, 5-15 parts of nardus thunbergii and 10-20 parts of mistletoe.

3. The Chinese medicine composition according to claim 1, characterized in that The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 15 parts of cinnamon twig, 10 parts of roasted liquorice root, 25 parts of calcined dragon bone, 25 parts of calcined oyster shell, 15 parts of cinnamon bark, 15 parts of salvia miltiorrhiza, 15 parts of chuanxiong, 10 parts of bupleurum, 10 parts of white peony root, 10 parts of fructus aurantii, 15 parts of sophora flavescens, 10 parts of nardus thunbergii and 15 parts of mistletoe.

4. The Chinese medicine composition according to any one of claims 1 to 3, characterized in that The traditional Chinese medicine composition also includes a pharmaceutically acceptable carrier.

5. The Chinese medicine composition according to any one of claims 1 to 3, characterized in that The dosage form of the Chinese medicine composition is an oral dosage form.

6. The Chinese medicine composition according to claim 5, characterized in that The oral dosage form is a decoction.

7. Use of the traditional Chinese medicine composition according to any one of claims 1 to 6 in the preparation of a drug for treating premature ventricular contractions.

8. The use according to claim 7, characterized in that The treatment of ventricular premature contraction includes reducing the number of ventricular premature contraction attacks, reducing the 24-hour ventricular premature contraction load, and improving clinical symptoms of palpitations and cardiac arrest.

9. The use according to claim 7, characterized in that The drug for treating premature ventricular contraction includes a Chinese patent medicine prepared from the Chinese medicine composition alone, or a Chinese and Western medicine composite preparation prepared by adding a chemical drug for treating arrhythmia conventionally in clinical practice.

Images